This handout is for thyrotoxicosis-precipitated atrial flutter. Your care team identified this based on: palpitations + tachycardia + heat intolerance + tremor + weight loss + diaphoresis in patient with new-onset afl/af — thyrotoxicosis screen mandatory.
Other reasons your team may use this plan: atrial flutter on 12-lead ecg + suppressed tsh (<0.1) + elevated free t4/t3 — thyrotoxicosis-precipitated afl confirmed; known graves disease, toxic multinodular goiter, or toxic adenoma + new afl/af presentation; burch-wartofsky score ≥45 (thyroid storm) + afl with hemodynamic instability — emergent simultaneous storm + arrhythmia management.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| propranolol | 40 mg PO q4-6h (or 1 mg IV slow push q5min up to 5 mg in storm); titrate to HR 80-110 | PO/IV | q4-6h PO / titrate IV | PREFERRED BB in thyrotoxicosis — at high doses (≥160 mg/d) reduces peripheral T4→T3 conversion via 5'-deiodinase inhibition; rapid symptom palliation (palpitations, tremor, anxiety); ATA 2016 (PMID 27521067) Class I; ACC/AHA 2024 rate control |
| metoprolol_tartrate | 5 mg IV q5min × 3 (max 15 mg) then 25-50 mg PO BID | IV/PO | IV q5min × 3 → PO BID | Acceptable alternative to propranolol (does not reduce T4→T3 conversion but effective rate control); ACC/AHA 2024 (PMID 38753446) Class I |
| esmolol | 500 mcg/kg IV bolus then 50-300 mcg/kg/min infusion | IV | continuous infusion | Ultra-short half-life (~9 min) allows rapid titration in unstable patients; useful in storm to avoid prolonged β-blockade if hemodynamics shift |
| methimazole | 20-30 mg/d PO (divided BID-TID for first weeks then once daily) | PO | daily | PREFERRED thionamide — lower hepatotoxicity than PTU; once-daily dosing improves adherence; ATA 2016 (PMID 27521067) Class I; titrate to euthyroid TSH then RAI/thyroidectomy decision |
| propylthiouracil | 100 mg PO q8h (then up to 300-400 mg/d in storm) | PO | q8h | Use 1st trimester (methimazole teratogenic — aplasia cutis, choanal/esophageal atresia); preferred in storm (additionally blocks peripheral T4→T3 conversion at high doses); switch to methimazole at start of 2nd trimester; ATA 2016 |
| apixaban | 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) | PO | BID | PREFERRED AC during active thyrotoxicosis — warfarin dosing erratic during hyperthyroid → euthyroid transition (clotting factor metabolism shifts dramatically); ARISTOTLE foundational (PMID 21870978); ACC/AHA 2024 (PMID 38753446) class I; thyrotoxicosis-AFL/AF generally warrants AC even at low CHA2DS2-VASc per ATA 2016 endorsement |
| rivaroxaban | 20 mg with food (15 mg if CrCl 15-50) | PO | once daily | ROCKET-AF alternative DOAC; once-daily dosing improves adherence |
| warfarin | 5 mg daily; INR target 2-3 with WEEKLY monitoring during thyroid transition | PO | daily | AVOID if possible during active thyrotoxicosis — clotting factor metabolism shifts erratically; if must use, weekly INR + dose adjustments expected; transition to DOAC once euthyroid if eligible |
| hydrocortisone | 100 mg IV q8h (or dexamethasone 2 mg IV q6h) | IV | q8h | STORM PROTOCOL — blocks peripheral T4→T3 conversion via 5'-deiodinase inhibition + treats relative adrenal insufficiency of storm + suppresses Graves autoimmune component; ATA 2016 + Burch-Wartofsky |
| cholestyramine | 4 g PO QID | PO | QID | STORM ADJUNCT — interrupts enterohepatic recycling of thyroid hormone; ATA 2016 IIa; useful in storm or refractory thyrotoxicosis |
| potassium_iodide_sski | 5 drops (250 mg) PO q6h, MUST start ≥1 h AFTER thionamide | PO | q6h | STORM ADJUNCT — Wolff-Chaikoff effect blocks new thyroid hormone synthesis + release; CRITICAL TIMING — give ≥1 h AFTER first thionamide dose to avoid jodbasedow (substrate for synthesis); ATA 2016 |
Plan: Thyrotoxicosis-precipitated atrial flutter — BB-first rate control (propranolol mechanism-aware) + AVOID AMIODARONE + thionamide initiation + DOAC during active thyrotoxicosis — ACC/AHA 2024 (PMID 38753446) + ATA 2016 (PMID 27521067)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Endocrinology q4-6 wk during thionamide titration to euthyroid; definitive therapy decision (RAI 6-12 mo of thionamide, OR thyroidectomy if large goiter/compressive symptoms/pregnancy planned/RAI-ineligible, OR continued thionamide); cardiology surveillance for AFL recurrence post-euthyroid (most resolve; ablation if persistent); long-term AC reassessment (typically discontinue once euthyroid + sustained NSR + low CHA2DS2-VASc; continue if recurrent or score ≥2)
Guideline: 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2024 AF (Van Gelder PMID 39050851) + 2016 ATA Hyperthyroidism Guidelines (Ross PMID 27521067)